MannKind, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on the stock and has a $9.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes’s rating is based on a combination of factors that highlight MannKind’s potential for growth despite recent market reactions. Although the company reported lower-than-expected earnings for Tyvaso DPI royalties and collaboration revenue, it showed stronger-than-anticipated results for Afrezza and V-Go. This indicates a positive trend in some of its key products. Additionally, MannKind’s decision to secure a $500 million credit facility, despite having a strong balance sheet, reflects its strategic move to enhance financial flexibility for future investments in product expansion and potential acquisitions.
Furthermore, the market’s reaction to the 2Q25 results, which saw a 10% drop in MNKD’s stock, seems to overlook the company’s upcoming value drivers. These include the anticipated Afrezza pediatric launch and the promising pipeline developments for MNKD-101 and MNKD-201. The upcoming TETON-2 study data could serve as a significant catalyst, potentially reversing the stock’s current weakness. Folkes believes that MannKind’s stock is fundamentally undervalued and that the company’s strategic initiatives and upcoming catalysts position it well for future growth, justifying the Buy rating.
Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Cardiol Therapeutics, and Eupraxia Pharmaceuticals. According to TipRanks, Folkes has an average return of -6.2% and a 34.48% success rate on recommended stocks.
In another report released on July 30, Wedbush also maintained a Buy rating on the stock with a $11.00 price target.